Strong preclinical data on Basilea's BAL30072
Swiss drugmaker Basilea reported preclinical data on its novel antibiotic BAL30072 showing high activity against some of the most difficult-to-treat multi-resistant Gram-negative bacteria in in vitro and in vivo models of infection.
Presented at the 6th Anti-Infectives Partnering & Deal-Making Summit in Boston, USA, BAL30072 was effective against Pseudomonas and Acinetobacter, both in susceptibility tests and in animal models of infection.
According to Basilea, the novel siderophore monobactam antibiotic's unique pattern of penicillin-binding protein inhibition and bactericidal mode of action confer potent activity against Gram-negative non-fermentors. These properties enable BAL30072 to overcome most of the genetically-defined factors of beta-lactam resistance, the company stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze